SG11201806251WA - Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody - Google Patents
Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibodyInfo
- Publication number
- SG11201806251WA SG11201806251WA SG11201806251WA SG11201806251WA SG11201806251WA SG 11201806251W A SG11201806251W A SG 11201806251WA SG 11201806251W A SG11201806251W A SG 11201806251WA SG 11201806251W A SG11201806251W A SG 11201806251WA SG 11201806251W A SG11201806251W A SG 11201806251WA
- Authority
- SG
- Singapore
- Prior art keywords
- her2
- breast cancer
- international
- hrg
- treating
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title abstract 6
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 4
- 238000002648 combination therapy Methods 0.000 title abstract 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000002124 endocrine Effects 0.000 abstract 2
- 229960002258 fulvestrant Drugs 0.000 abstract 2
- 229960003881 letrozole Drugs 0.000 abstract 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 abstract 2
- 230000001394 metastastic effect Effects 0.000 abstract 2
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229950008834 seribantumab Drugs 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 abstract 1
- 235000014036 Castanea Nutrition 0.000 abstract 1
- 241001070941 Castanea Species 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 abstract 1
- 229960004390 palbociclib Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662308783P | 2016-03-15 | 2016-03-15 | |
| US201662356127P | 2016-06-29 | 2016-06-29 | |
| US201662431242P | 2016-12-07 | 2016-12-07 | |
| PCT/US2017/022517 WO2017160990A1 (en) | 2016-03-15 | 2017-03-15 | Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201806251WA true SG11201806251WA (en) | 2018-08-30 |
Family
ID=58428399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201806251WA SG11201806251WA (en) | 2016-03-15 | 2017-03-15 | Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20190091227A1 (ja) |
| EP (1) | EP3429623A1 (ja) |
| JP (1) | JP2019508428A (ja) |
| KR (1) | KR20180119570A (ja) |
| CN (1) | CN109310754A (ja) |
| AU (1) | AU2017235450A1 (ja) |
| BR (1) | BR112018068512A2 (ja) |
| CA (1) | CA3011949A1 (ja) |
| IL (1) | IL260935A (ja) |
| MX (1) | MX2018011054A (ja) |
| SG (1) | SG11201806251WA (ja) |
| WO (1) | WO2017160990A1 (ja) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10449195B2 (en) | 2016-03-29 | 2019-10-22 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical formulation of palbociclib and a preparation method thereof |
| KR20190082989A (ko) | 2016-12-01 | 2019-07-10 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체 |
| WO2020106330A1 (en) * | 2018-07-18 | 2020-05-28 | Pillsy, Inc. | Smart drug delivery and monitoring device, kit, and method of use for pill compounds |
| JP6952747B2 (ja) * | 2018-09-18 | 2021-10-20 | ファイザー・インク | がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ |
| MX2021008918A (es) | 2019-01-31 | 2021-08-24 | Ionis Pharmaceuticals Inc | Moduladores de expresion yap1. |
| US20220125777A1 (en) * | 2019-02-01 | 2022-04-28 | Pfizer Inc. | Combination of a cdk inhibitor and a pim inhibitor |
| US20210060008A1 (en) * | 2019-08-26 | 2021-03-04 | Arvinas Operations, Inc. | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| CA3182018A1 (en) * | 2020-05-12 | 2021-11-18 | Genentech, Inc. | Treatment of breast cancer using combination therapies comprising gdc-9545 and a cdk4/6 inhibitor |
| CN114306245A (zh) | 2020-09-29 | 2022-04-12 | 深圳市药欣生物科技有限公司 | 无定形固体分散体的药物组合物及其制备方法 |
| JP2024509914A (ja) * | 2021-03-11 | 2024-03-05 | エレベーション オンコロジー， インコーポレイテッド | ニューレグリン１（ｎｒｇ１）遺伝子融合に関連する腫瘍を処置するための抗ｅｒｂｂ３（ｈｅｒ３）モノクローナル抗体の投与量および投与 |
| WO2023107525A1 (en) * | 2021-12-10 | 2023-06-15 | Eli Lilly And Company | Cdk4 and 6 inhibitor in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in patients previously treated with a cdk4 and 6 inhibitor |
| WO2023230286A2 (en) * | 2022-05-25 | 2023-11-30 | Onconova Therapeutics, Inc. | Methods and compositions for treating cancer |
| WO2023230288A1 (en) * | 2022-05-25 | 2023-11-30 | Onconova Therapeutics, Inc. | Methods and compositions for treating cancer |
| CN115068613A (zh) * | 2022-07-07 | 2022-09-20 | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | 泛tki在治疗hr阳性her2低表达乳腺癌的应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| EP1189641B1 (en) * | 1999-06-25 | 2009-07-29 | Genentech, Inc. | HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| PL2716301T3 (pl) | 2007-02-16 | 2017-10-31 | Merrimack Pharmaceuticals Inc | Przeciwciała przeciw ERBB3 i ich zastosowania |
| EP2132229B1 (en) | 2007-03-01 | 2016-05-11 | Symphogen A/S | Recombinant anti-epidermal growth factor receptor antibody compositions |
| EA022884B1 (ru) | 2008-08-15 | 2016-03-31 | Мерримак Фармасьютикалз, Инк. | СПОСОБ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ С ИСПОЛЬЗОВАНИЕМ АНТИ-ErbB3 АНТИТЕЛА |
| ES2572728T3 (es) | 2009-03-20 | 2016-06-02 | F. Hoffmann-La Roche Ag | Anticuerpos anti-HER biespecíficos |
| DK2516469T3 (en) | 2009-12-22 | 2016-05-02 | Roche Glycart Ag | ANTI-HER3 antibodies and uses thereof |
| DK2544680T3 (en) | 2010-03-11 | 2015-04-27 | Merrimack Pharmaceuticals Inc | USE OF ErbB3 INHIBITORS IN TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER |
| CA2795799C (en) | 2010-04-09 | 2018-09-25 | Aveo Pharmaceuticals, Inc. | Anti-erbb3 antibodies |
| US9238080B2 (en) | 2010-05-21 | 2016-01-19 | Merrimack Pharmaceuticals, Inc. | Bi-specific fusion proteins |
| CU24094B1 (es) | 2010-08-20 | 2015-04-29 | Novartis Ag | Anticuerpos para el receptor 3 del factor de crecimiento epidérmico(her3) |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| AU2012211258A1 (en) | 2011-01-27 | 2013-03-21 | Merrimack Pharmaceuticals, Inc. | Treatment of advanced solid stage tumors using anti-ErbB3 antibodies |
| EA201300996A1 (ru) * | 2011-03-11 | 2014-01-30 | Мерримак Фармасьютикалс, Инк. | Использование ингибиторов рецепторов семейства egfr в лечении гормонорезистентного рака молочной железы |
| KR20140063578A (ko) | 2011-06-30 | 2014-05-27 | 메리맥 파마슈티컬즈, 인크. | 부인과 암들의 치료를 위해 파크리탁셀과 조합한 항-ｅｒｂｂ３ 항체들 |
| AU2012294326A1 (en) | 2011-08-10 | 2013-03-21 | Merrimack Pharmaceuticals, Inc. | Treatment of advanced solid tumors using combination of anti-ErbB3 immunotherapy and selected chemotherapy |
| US9220775B2 (en) | 2011-11-23 | 2015-12-29 | Medimmune Llc | Binding molecules specific for HER3 and uses thereof |
| WO2013138371A1 (en) | 2012-03-12 | 2013-09-19 | Merrimack Pharmaceuticals, Inc. | Methods for treating pancreatic cancer using combination therapies comprising an anti-erbb3 antibody |
| JOP20200097A1 (ar) * | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
| BR112016002465B1 (pt) * | 2013-08-14 | 2022-09-20 | Novartis Ag | Combinação farmacêutica e seu uso |
| WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
-
2017
- 2017-03-15 JP JP2018544502A patent/JP2019508428A/ja active Pending
- 2017-03-15 BR BR112018068512A patent/BR112018068512A2/pt not_active Application Discontinuation
- 2017-03-15 SG SG11201806251WA patent/SG11201806251WA/en unknown
- 2017-03-15 MX MX2018011054A patent/MX2018011054A/es unknown
- 2017-03-15 US US16/084,442 patent/US20190091227A1/en not_active Abandoned
- 2017-03-15 WO PCT/US2017/022517 patent/WO2017160990A1/en active Application Filing
- 2017-03-15 KR KR1020187023317A patent/KR20180119570A/ko unknown
- 2017-03-15 CA CA3011949A patent/CA3011949A1/en not_active Abandoned
- 2017-03-15 EP EP17714105.8A patent/EP3429623A1/en not_active Withdrawn
- 2017-03-15 AU AU2017235450A patent/AU2017235450A1/en not_active Abandoned
- 2017-03-15 CN CN201780011269.1A patent/CN109310754A/zh active Pending
-
2018
- 2018-08-01 IL IL260935A patent/IL260935A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN109310754A (zh) | 2019-02-05 |
| JP2019508428A (ja) | 2019-03-28 |
| MX2018011054A (es) | 2019-01-21 |
| CA3011949A1 (en) | 2017-09-21 |
| WO2017160990A1 (en) | 2017-09-21 |
| AU2017235450A1 (en) | 2018-08-16 |
| IL260935A (en) | 2018-10-31 |
| BR112018068512A2 (pt) | 2019-01-22 |
| US20190091227A1 (en) | 2019-03-28 |
| KR20180119570A (ko) | 2018-11-02 |
| EP3429623A1 (en) | 2019-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201806251WA (en) | Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody | |
| SG11201900344YA (en) | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor | |
| SG11201806861SA (en) | Combination therapy with anti-cd73 antibodies | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201806515RA (en) | Eribulin-based antibody-drug conjugates and methods of use | |
| SG11201900677SA (en) | Combination therapies of chimeric antigen receptors adn pd-1 inhibitors | |
| SG11201810034XA (en) | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | |
| SG11201804839WA (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| SG11201806261XA (en) | Bcma antibodies and use of same to treat cancer and immunological disorders | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201807538PA (en) | Crispr-cpf1-related methods, compositions and components for cancer immunotherapy | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201805645QA (en) | Lsd1 inhibitors | |
| SG11201901126UA (en) | Combination therapy for cancer | |
| SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof | |
| SG11201804647TA (en) | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201811559WA (en) | Cancer treatment combinations | |
| SG11201811292RA (en) | Compositions and methods for the depletion of cells | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201810951RA (en) | Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201809024UA (en) | Cancer immunotherapy by immune activation or immune modulation via globo series antigens | |
| SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
| SG11201808676RA (en) | Methods of treating pediatric cancers |